Arsthinol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 15:30, 30 November 2015 (Chembox: move all ATCCode-parameters into section Parmacology. See WP:Chembox talk#Drugbank_and_ATC_positioning (+minor param corrections) (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457817818 | ImageFile = Arsthinol.svg | ImageFile_Ref = | ImageSize = 244 | ImageName = Structural formula of arsthinol | SystematicName = N-{2-Hydroxy-5-[4-(hydroxymethyl)-1,3,2-dithiarsolan-2-yl]phenyl}acetamide |Section1=! colspan=2 style="background: #f8eaba; text-align: center;" |Identifiers

|-

|

|

|-

|

3D model (JSmol)

|

|-



| ChemSpider

|

|-

| ECHA InfoCard | 100.003.965 Edit this at Wikidata |- | EC Number

|

  • 204-361-7

|-


| KEGG

|

|-

|

|

|-

| UNII

|

|-

|

|

|-

| colspan="2" |

  • InChI=1S/C11H14AsNO3S2/c1-7(15)13-10-4-8(2-3-11(10)16)12-17-6-9(5-14)18-12/h2-4,9,14,16H,5-6H2,1H3,(H,13,15) checkY
    Key: MRUDSZSRLQAPOG-UHFFFAOYSA-N checkY
  • InChI=1/C11H14AsNO3S2/c1-7(15)13-10-4-8(2-3-11(10)16)12-17-6-9(5-14)18-12/h2-4,9,14,16H,5-6H2,1H3,(H,13,15)
    Key: MRUDSZSRLQAPOG-UHFFFAOYAP

|-

| colspan="2" |

  • CC(=O)NC1=C(O)C=CC(=C1)[As]1SCC(CO)S1
  • O=C(Nc2cc([As]1SCC(S1)CO)ccc2O)C

|- |Section2=! colspan=2 style="background: #f8eaba; text-align: center;" |Properties

|-

|

| C11H14AsNO3S2

|- | Molar mass

| 347.28 g·mol−1

|- |Section6=! colspan=2 style="background: #f8eaba; text-align: center;" |Pharmacology

|-

|

| P01AR01 (WHO) QP51AD01 (WHO) |-


|

| Oral |- | colspan=2 style="text-align:left; background-color:#eaeaea;" | Pharmacokinetics: |- |-

| style="padding-left:1em;" |

| 89 % Hepatic[1]

|- |- }} Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite)[2] and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years latter by Endo Products (Balarsen, Tablets, 0.1 g).[3] Among trivalent organoarsenicals, arthinol was considered as very well tolerated.[4] Recently, it was studied for its anticancer activity.[5][6]


References

  1. ^ Cristau B, Chabas ME, Placidi M. (1975) Voies et cinétiques d'excrétion de l'arsenic chez le Cobaye après injection de divers médicaments organo-arséniés. Ann Pharm Fr 33: 577-89
  2. ^ Friedheim EAH. (1949) A Five Day Peroral Treatment of Yaws with STB, a New Trivalent Arsenical. Am J Trop Med Hyg s1-29: 185
  3. ^ Anonyme. (1953) New and nonofficial remedies; arsthinol. J Am Med Assoc 152: 531
  4. ^ Brown CH, Gebhart WF, Reich A. (1956) Intestinal amebiasis: incidence, symptoms, and treatment with arsthinol (Balarsen). JAMA 160: 360-363
  5. ^ Gibaud S, Alfonsi R, Mutzenhardt P et al. (2006) (2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. J Organomet Chem 691: 1081-1084
  6. ^ Becherirat, S., Lanhers, M.-C., Socha, M., Yemloul, M., Astier, A., Loboda, C., Aniceto N., Gibaud S. (2013) The antitumor effects of an arsthinol-cyclodextrin complex in an heterotopic mouse model of glioma. Eur J Pharm Biopharm, doi: http://dx.doi.org/10.1016/j.ejpb.2013.06.021